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Epinephrine (adrenaline) is the treatment of choice for anaphylaxis. While other medications, including H1-antihistamines,
H2-antihistamines, corticosteroids, and inhaled beta-2 agonists are often used to treat anaphylaxis in the emergency
setting, none of these medications has been shown to reverse anaphylaxis. Fatal anaphylaxis is related to the delayed
use of epinephrine. In community settings, epinephrine is available as an auto-injector in two doses, 0.15 mg and
0.3 mg. The recommended dose for children is 0.01 mg per kilogram. For infants at risk of anaphylaxis in the community,
there are few options with regard to providing an optimal epinephrine dose for first-aid treatment. The Canadian Society
of Allergy and Immunology (CSACI) therefore recommends, for the child weighing less than 15 kg, given the lack
of a suitable alternative, prescribing the 0.15 mg epinephrine autoinjector. Adverse effects of an epinephrine dose
of 0.15 mg given intramuscularly in infants or children weighing less than 15 kg are expected to be mild and transient at
the plasma epinephrine concentrations achieved; therefore, these effects need to be measured against the consequences
of not receiving epinephrine at all, which can include fatality.
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anaphylaxis [1–3]. No other medication decreases airway
edema (via its alpha-1 adrenergic effects), acts as a vaso-
constrictor and relieves shock (via its alpha-1 adrenergic
effects), has inotropic and chronotropic effects (via its
beta-1 adrenergic effects), leads to bronchodilation (via
its beta-2 adrenergic effects), and decreases mediator
release (through mast cell stabilization) [1]. While other
medications, including H1-antihistamines, H2-antihista-
mines, corticosteroids, and inhaled beta-2 agonists are
often used to treat anaphylaxis in the emergency setting,
none of these medications has been shown to reverse
anaphylaxis [1]. While the same can be said regarding
epinephrine, as there are no randomized double-blind
controlled trials comparing epinephrine to placebo, robust
epidemiological data including studies of fatal anaphylaxis,
mechanistic data and animal studies, and years of clinical
experience confirm that prompt injection of epinephrine
is the best treatment of life-threatening anaphylaxis. Scru-
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life-threatening anaphylaxis [4].
As outlined in the 2011 World Allergy Organization
Guidelines, management of anaphylaxis includes the fol-
lowing instructions: 1) Have a written Emergency Action
Plan; 2) Remove exposure to the trigger, if relevant/possible;
3) Assess the person’s reaction; 4) Call for help; 5) Inject
epinephrine IM in the mid-outer aspect of the thigh; 6)
Place the child on the back or in a position of comfort if
there is respiratory distress and/or vomiting; elevate the
lower extremities [1].
In community settings, epinephrine is available as an
auto-injector in two doses, 0.15–0.3 mg. The recommended
dose for children is 0.01 mg per kilogram, which can be
repeated every 5–15 min as clinically indicated [1]. The
Canadian Paediatric Society recommends using an epi-
nephrine autoinjector 0.15 mg for children who weigh be-
tween 10 and 25 kg [2]. EpiPen® and Allerject® product
monographs suggest that EpiPen®/Allerject® 0.15 mg should
be given for children weighing between 15 and 30 kg and
for those weighing less than 15 kg, 911 should be called
[5, 6]. For infants at risk of anaphylaxis in the community,
there are few options with regard to providing an optimal
epinephrine dose for first-aid treatment [2, 7].article distributed under the terms of the Creative Commons Attribution License
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that the needle length may not be sufficient to penetrate
the subcutanous tissue and reach the muscle. Stetcher et al.
found that the needle lengths were not long enough to
reach the muscle in a significant number of children [8]. In
infants, the opposite is a concern: is the needle too long
[9]? The hypothetical risks need to be balanced with the
clear potential benefits.
Most anaphylaxis in infants occurs in community set-
tings where cow’s milk is the most common trigger [10].
For outpatient use, the recommended epinephrine dose
of 0.01 mg per kg is not currently available in auto-
injector form less than 0.15 mg. In order to meet these
dosing recommendations in smaller children, some phy-
sicians prescribe ampules of epinephrine, and parents
have been instructed to draw up and administer epi-
nephrine using ampules and syringes. This method may
lead to inaccurate dosing and delays in administration
[11]. A more acceptable solution, in the absence of a
lower dose of epinephrine auto-injector, would be to
prescribe the 0.15 mg epinephrine auto-injector dose
[11–13].
This position statement will address a number of ques-
tions regarding epinephrine administration/prescribing
suggestions for the infant under 15 kg who is at risk for
anaphylaxis. It specifically addresses the following ques-
tions: What are possible consequences of administering
a larger than recommended dose of epinephrine? Are
there other ways to prescribe the recommended dose of
epinephrine? What are the consequences of not admin-
istering epinephrine? What does the Canadian Society
for Allergy and Clinical Immunology suggest for the in-
fant less than 15 kg?
1) What are possible consequences of an epinephrine
overdose?
During a randomized, double-blind, parallel-group
study, children age 4–8 years weighing 15–30 kg,
and at risk of anaphylaxis in the community,
self-injected either 0.15 mg or 0.3 mg of epinephrine.
Transient dose-related adverse effects were observed
after these injections. All children receiving the
0.15 mg dose developed pallor, and some also
experienced tremor and anxiety. All children receiving
the 0.3 mg dose experienced pallor, tremor, anxiety,
and palpitations, and two children developed headache
and nausea. One child who weighed 30 kg and received
0.3 mg epinephrine dose developed transient prolonga-
tion of the QTc interval [14]. Serious adverse events
have been described in adult patients with anaphylaxis
who received overdoses of IV epinephrine (cardiac
resuscitation doses of 1 mg of 1:10 000 IV push bolus
were given), or when rapid IV infusions were given
[15, 16].2) Are there other ways to prescribe the recommended
dose of epinephrine?
Given that currently the only epinephrine doses
available in auto-injectors are 0.15 mg or 0.3 mg,
another option is to prescribe 1 mL ampoules of
epinephrine and 1 mL syringes and instruct par-
ents how to draw up the prescribed dose for treat-
ment of an anaphylaxis episode. One study specifically
evaluated the ability of parents, physicians and nurses
to quickly, and correctly draw up epinephrine via a
syringe and ampoule. The results indicated that even
in a calm setting, compared to the healthcare
professionals, parents took significantly longer to
draw up the dose, and the dose ultimately drawn
up by parents had a 40-fold range of epinephrine
content. Other concerns identified included
difficulty removing air from the syringe without
ejecting the epinephrine dose from the syringe,
and in one instance a parent shattering the ampoule.
Given that the goal of prescribing or providing a syringe
and ampoule is to be more precise about epinephrine
dosing, this is not an adequate solution [11].
3) What are the consequences of not administering
epinephrine to infants weighing less than 15 kg?
Severe, biphasic and fatal anaphylaxis have been
reported in infants as young 7 weeks of age,
highlighting that fatal anaphylaxis can occur in
infancy [17]. Other studies have suggested that
delay in administration of epinephrine can lead
to more serious outcomes [18, 19]. The use of
epinephrine is associated with lower
hospitalization rates and reduced mortality [20].
Early recognition of anaphylaxis and prompt use
of epinephrine can be particularly challenging in
infants, who cannot communicate their
symptoms and do not always develop hives or
other obvious cutaneous signs of anaphylaxis
[21].
4) What does the Canadian Society for Allergy and
Clinical Immunology suggest for the infant less
than 15 kg?
The potential consequences of not administering
epinephrine to a child with anaphylaxis outweigh
the potential consequences of administering higher
than recommended doses of epinephrine. Given the
lack of suitable alternatives, the CSACI suggests that
an epinephrine autoinjector of 0.15 mg be prescribed
for children weighing less than 15 kg (including less
than 10 kg) (expert opinion). Ideally, epinephrine
auto-injectors containing a lower epinephrine dose,
for example 0.1 mg, would be recommended for use
in this population.
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For the child weighing less than 15 kg, given the lack of
a suitable alternative, we recommend prescribing the
0.15 mg epinephrine autoinjector. Adverse effects of an
epinephrine dose of 0.15 mg given intramuscularly in in-
fants or children weighing less than 15 kg are expected
to be mild and transient at the plasma epinephrine con-
centrations achieved; therefore, these effects need to be
measured against the consequences of not receiving epi-
nephrine at all, which can include fatality. The majority
of physicians now prescribe an epinephrine auto-injector
0.15 mg for infants and children weighing less than
15 kg, in the absence of a weight-appropriate alternative
(i.e., an epinephrine auto-injector containing lower doses).
We discourage the prescription of epinephrine ampoules
and syringes. Fatal and near-fatal outcomes are related to
delayed administration of epinephrine, which should be
used promptly, as it is the only medication known to
reverse the life-threatening effects of anaphylaxis.Key points
– Epinephrine is the best medication to reverse
anaphylaxis.
– Fatal anaphylaxis is related to the delayed use of
epinephrine.
– It is essential to teach caregivers how to recognize
anaphylaxis and promptly and correctly use the
epinephrine auto-injector prescribed for the infant.
– We suggest prescribing a 0.15 mg epinephrine auto-
injector for a child with a history of anaphylaxis
weighing less than 15 kg, given the potential serious
consequences of anaphylaxis, and the potential but
generally mild adverse effects of epinephrine,.
– Ideally, epinephrine auto-injectors containing a
lower epinephrine dose, for example 0.1 mg, would
be recommended for use in this population.Abbreviations
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